At the annual conference of the American Academy of Neurology (AAN), which will be held from April 26 to May 3 in Philadelphia, will be presented to the successful outcome of Phase II clinical trial of two brand new compared to existing drugs for the prevention of migraine attacks, according to a press release AAN. Both drugs are used first for the prevention of migraine monoclonal antibody. The creators promise a new era of medicine in preventive therapy for this disease.

Target against which drugs work, also not previously been involved in order to prevent migraine attacks - monoclonal antibodies block the calcitonin gene-related peptide (CGRP), synthesized by cells of the central and peripheral nervous system neurotransmitter that plays a key role in the transmission of pain.

During the first tests of medicines, ALD403, 163 patients suffering from migraine attacks from five to 14 days per month or one placebo dose. Over the next six months, the group received the drug was observed 66 percent reduction in the number of attacks per month, compared to 52 percent reduction in the group receiving placebo. In 16 percent of the participants received the drug group attacks were completely absent for three months, which was not observed in the placebo group. Difference in side effects between the groups was observed.

In trials of another drug, LY2951742, 217 patients suffering from migraine from 4 to 14 days a month, for three months received twice weekly subcutaneous injections of placebo or drug. In the group receiving therapy, there was a 63 percent reduction in seizure frequency per month compared with a 42 percent decline in the placebo group. In patients receiving the drug were noted side effects such as pain at the injection site, pain in the abdomen and upper respiratory tract infection, but in general medicine was found to be safe and well tolerated.

Although both drugs is still the third phase of clinical trials, according to the representative of the University of California (San Francisco) Godsbi Peter (Peter Goadsby), participated in the creation and testing of both drugs, the results are potentially promising new era in preventive treatment of migraine.

Migraine affects about 14 percent of the adult population and, according to the global health research people on Earth Global Burden of Disease Survey in 2010, is the seventh of disabling diseases.

International research group led by Professor Chen has developed a new generation of potentially safer and more cost-effective therapies against West Nile virus etc, and other pathogens.

Scientists applied therapy based on monoclonal antibodies and their derivatives.

For the purposes of the study monoclonal antibodies are derived from tobacco plants, which is promising to change the image of the plant, which are believed to cause cancer of the lung.

The antibodies are directed against proteins located on the surface of the virus.

The main objective of the study is to create innovative, sustainable and affordable therapy that also be a cheap solution to combat the global threat of West Nile virus.

One approach is the development of therapeutic antibodies that bind to receptors which may help of the monoclonal antibodies to cross into the brain.

In a new study, the researchers developed a half-dozen new options that could assist in the implementation monoclonal antibodies that can be effectively targeted to the brain and to neutralize the dangerous virus.

The final results of the study show 90% success in preventing letalnit development in experimental conditions.

This is the first case of such an effect, leading to the neutralization of the virus.

Dr. Chen results are motivating the development of plant-based therapy that dramatically reduce the cost of commercial production of monoclonal antibodies.

The virus is spread by infected mosquitoes and affect the central nervous system.

Infection can cause serious, life-altering and even fatal disease.

Until now, however, is not available or effective drug therapy for dealing with infection.

Specificity: In a simple ELISA, 4955-0308 only reacts with HSV-2 gC antigen. It does not react with gD or any other antigen preparations from HSV-1.

Product name: MOUSE ANTI HERPES SIMPLEX VIRUS 2 gC

Catalog Num.: 4955-0308

Quantity: 0.2 mg

Target: HSV-2 gC

Clone: 1073/53

Host: Mouse

Applications: ELISA

Conjugate/Tag/Label: Unconjugated

Purity: Ammonium sulfate precipitation

Reactivity: Herpes Simplex Virus

Datasheet: Monoclonal Mouse anti-HSV-2 gC antibody

Price: 350 €

More: Antibodies

Gentaur provides a wide range of specialist antibodies, primarily to aid research in the cellular stress, heat shock, ion channel and transporter fields of study. However we also provide antibodies as research tools for Apoptosis, Cell Signaling and Post-translational Modification amongst others.

If you need help finding the reagent that meets your requirements, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it.

HO-1 (Rat) Antibody

Catalog#: SPC-207D
Package size: 100ug
Type: Polyclonal
Datasheet: SPC 207 Heme oxgenase 1 Heat Shock Protein 32 (HO 1)
Description: Anti-HO-1 (Rat)

HSF1 Antibody

Catalog#: SPC-208D
Package size: 100ug
Type: Polyclonal
Datasheet: SPC 208 Heat Shock Factor 1 (HSF1)
Description: Anti-HSF1

LGI1 Antibody

Catalog#: SMC-461D
Package size: 100ug
Type: Monoclonal
Datasheet: SMC 461 LGI1
Description: Anti-LGI1

LRRK2/Dardarin Antibody

Catalog#: SMC-445D
Package size: 100ug
Type: Monoclonal
Datasheet: SMC 445 LRRK2 Dardarin N3
Description: Anti-LRRK2/Dardarin

PEX6 Antibody

Catalog#: SMC-470D
Package size: 100ug
Type: Monoclonal
Datasheet: SMC 470 PEX6
Description: Anti-PEX6

PINK1 Antibody

Catalog#: SMC-450D
Package size: 100ug
Type: Monoclonal
Datasheet: SMC 450 PINK1
Description: Anti-PINK1

Pan-QKI Antibody

Catalog#: SMC-467D
Package size: 100ug
Type: Monoclonal
Datasheet: SMC 467 Pan QKI
Description: Anti-Pan-QKI

SOD1 (UβB) Antibody

Catalog#: SPC-205D
Package size: 100ug
Type: Polyclonal
Datasheet: SPC 205 SOD1 (UBB) Oxidative Stress
Description: Anti-SOD1 (UβB)

SOD1 (EDI) Antibody

Catalog#: SPC-206D
Package size: 100ug
Type: Polyclonal
Datasheet: SPC 206 SOD1 (EDI) Oxidative Stress
Description: Anti-SOD1 (EDI)

TRAP1 Antibody

Catalog#: SPC-209D
Package size: 100ug
Type: Polyclonal
Datasheet: SPC 209 TRAP1 Heat Shock Protein
Description: Anti-TRAP1

Virus Core Antigen Detection

- Measures the p24 core protein of HIV-1
- Quantitation is performed on a standard microplate reader
- p24 Standard included

Overview: An anti-HIV p24 monoclonal coating antibody is adsorbed onto a microtiter plate. p24 antigen present in the sample or standard binds to the antibodies adsorbed on the plate; a FITC-conjugated mouse anti-p24 antibody is added and binds to p24 antigen captured by the first antibody.

Following incubation and wash steps, a HRP-conjugated mouse anti-FITC antibody is added and binds to the FITC conjugated anti-p24. Following unbound HRP-conjugated mouse anti-FITC antibody is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

A colored product is formed in proportion to the amount of p24 antigen present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from recombinant HIV-1 p24 protein and sample p24 concentration is then determined.

Storage: Store all kit reagents at 2° - 8°C. DO NOT FREEZE. When stored properly the kit is stable until the date indicated on the box label.

Download datasheet

Price: 486 Euro

More: Monoclonal Antibody

We are currently offering a comprehensive panel of antibodies specific for human Norovirus, including GII.4 2012 Sydney strain.  MAB223P through MAB228P have been tested across a broad range of strains, as reported in the table below.  In addition to being broadly cross reactive to GII.4 genotypes, MAB227P has demonstrated the ability to block ligand binding in surrogate neutralization assays.  MAB228P, developed against GI.1 1968 virus like particles (VLPs), has been shown to recognize additional GI types.  There are currently five known genogroups, of which three cause human disease: GI, GII, and GIV.  According to the CDC, since 2002 GII.4 has been the most common cause of Norovirus outbreaks.

The Cysticercosis Antigen (Ag) ELISA (Ref. 650501) is a sandwich Enzyme-Linked ImmunoSorbent Assay based on monoclonal antibodies for the qualitative determination of viable metacestodes (cysticerci) of Taenia spp. in human and porcine serum samples.

-  Analytical sensitivity: 1 cyst is detectable in certain conditions
- Incubation times: assay 45 minutes + sample prep <30 minutes
- Available format: 96T

Taenia solium cysticercosis is an infection of humans and pigs with metacestode larvae (cysticercus) of Taenia solium. Circulating antigen detection in serum is an important diagnostic method that indicates the presence of viable parasites. The monoclonal antibodies used in this assay are produced against excretory secretory products (ESP) of viable T. saginata cysticerci. The glycoprotein antigens detected by these monoclonal antibodies are present on the tegument and in the excretory secretory products of metacestodes.

The assay demonstrates the presence of viable cysticerci only, it does not detect degenerated or calcified cysticerci. In this respect, unlike antibody detection, measurement of circulating antigen levels allows differentiation of cysticercosis cases with viable parasites, with antigen levels correlating to the numbers and size of lesions. It can as such also provide a tool for serological monitoring of antiparasitic therapy in human or pigs: antigen levels drop rapidly after successful anthelminthic treatment.

Porcine cysticercosis

The assay is genus specific, not species specific. The assay does not allow the differentiation between infections of different Taenia species in pigs. In experimentally infected pigs, circulating antigens were first detected between 2 and 6 weeks post infection and remained present generally throughout an observation period of 6 months, even in pigs carrying only five to eight living cysts. The minimum number of living cysts, that could be detected using the Cysticercosis Ag ELISA, was one.

Human cysticercosis

Because T. solium is the only Taenia sp. causing cysticercosis in man, the test is specific. No cross-reactions were observed with sera from patients with other parasitologically and/or serologically confirmed infections. The sensitivity of the assay decreases when the number of viable cysts is low; infections with one viable cyst are often not detectable. Antigen levels are generally higher in extraparenchymal neurocysticercosis (NCC) (particularly subarachnoid NCC) than in intraparenchymal NCC; therefore, high antigen levels should lead one to suspect the presence of extraparenchymal NCC.

Download datasheet

Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells. Scientists from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.

Unlike other human therapeutic monoclonal antibodies, which can target only proteins that remain on the outside of cancer cells, the new monoclonal antibody, called ESK1, targets a protein that resides on the inside of the cell. ESK1 is directed at a protein called WT1, which is overexpressed in a range of leukemias and other cancers including myeloma and breast, ovarian, and colorectal cancers. WT1 is a high priority target for cancer drugs because it is an oncogenic protein, meaning that it supports the formation of cancer. In addition, it is found in few healthy cells, so there are less likely to be side effects from drugs that target it. "This is a new approach for attacking WT1, an important cancer target, with an antibody therapy. This is something that was previously not possible," said David A. Scheinberg, MD, PhD, Chair of the Sloan-Kettering Institute's Molecular Pharmacology and Chemistry Program and an inventor of the antibody. "There has not been a way to make small molecule drugs that can inhibit WT1 function. Our research shows that you can use a monoclonal antibody to recognize a cancer-associated protein inside a cell, and it will destroy the cell." 

The first studies of the antibody are showing promise in preclinical research as a treatment for leukemia as reported March 13, 2013, in Science Translational Medicine. "ESK1 represents a paradigm change for the field of human monoclonal antibody therapeutics," said Cheng Liu, PhD, President and Chief Executive Officer of Eureka Therapeutics. "This research suggests that human antibody therapy is no longer limited to targeting proteins present outside cancer cells, but can now target proteins within the cancer cell itself."

ESK1 was engineered to mimic the functions of a T cell receptor, a key component of the immune system. T cells have a receptor system that is designed to recognize proteins that are inside the cell. As proteins inside the cell get broken down as part of regular cellular processes, molecules known as HLA molecules carry fragments of those proteins -- known as peptides -- to the surface. When T cells recognize certain peptides as abnormal, the T cell kills the diseased cell. In the current study, the investigators showed that ESK1 alone was able to recognize WT1 peptides and kill cancer cells in the test tube and also in mouse models for two different types of human leukemia. "We were surprised that the antibody worked so well on its own," said Dr. Scheinberg, senior author of the paper. "We had originally expected that we might need to use the antibody as a carrier to deliver a drug or a radioactive therapy to kill the cancer cells, but this was not necessary."

Additional studies must be done in the laboratory before ESK1 is ready to be tested in patients. But the monoclonal antibody was engineered to be fully human, which should speed the time it takes to move the drug into the clinic. Researchers expect that the first clinical trials, for leukemia, could begin in about a year.

The antibody was developed under a collaborative effort between Memorial Sloan-Kettering and Eureka, which have jointly filed for patent protection. This work was supported by grants from the Leukemia and Lymphoma Society, the National Cancer Institute, the Sloan-Kettering Institute's Experimental Therapeutics Center and Technology Development Fund, the Commonwealth Foundation for Cancer Research, the Tudor and Glades Foundations, the Merker Fund, the Lymphoma Foundation, and the Mesothelioma Applied Research Foundation.

http://www.sciencedaily.com

Catalog number : 2125-96T
Quantity:
Availability: Yes

Details: This kit is a solid phase-phase sandwich enzyme linked immuno sorbent assay (ELISA). Samples, including standards of known target protein concentrations and unknowns are pipetted into these wells. During the first incubation, the target protein antigen and a biotinylated monoclonal antibody specific for target protein are simultaneously incubated. After washing, the enzyme (streptavidin-peroxydase) is added. After incubation and washing to remove the entire unbound enzyme, a substrate solution which is acting on the bound enzyme is added to induce a colored reaction product. The intensity of this colored product is directly proportional to the concentration of target protein present in the samples.

 Price: 173 EUR